Affiliation:
1. Department of Internal Medicine Maastricht University Medical Center Maastricht The Netherlands
2. School for Cardiovascular Diseases (CARIM) Maastricht The Netherlands
3. Top Institute of Food and Nutrition (TIFN) Wageningen The Netherlands
4. Amsterdam Diabetes Center, Department of Internal and Vascular Medicine Amsterdam UMC Locatie AMC Amsterdam The Netherlands
5. Department of Epidemiology Maastricht University Maastricht The Netherlands
6. Care and Public Health Research Institute (CAPHRI) Maastricht The Netherlands
7. Tohoku University Graduate School of Medicine Sendai Japan
Abstract
AbstractAimTo investigate the effects of pyridoxamine (PM), a B6 vitamer and dicarbonyl scavenger, on glycation and a large panel of metabolic and vascular measurements in a randomized double‐blind placebo‐controlled trial in abdominally obese individuals.Materials and methodsIndividuals (54% female; mean age 50 years; mean body mass index 32 kg/m2) were randomized to an 8‐week intervention with either placebo (n = 36), 25 mg PM (n = 36) or 200 mg PM (n = 36). We assessed insulin sensitivity, β‐cell function, insulin‐mediated microvascular recruitment, skin microvascular function, flow‐mediated dilation, and plasma inflammation and endothelial function markers. PM metabolites, dicarbonyls and advanced glycation endproducts (AGEs) were measured using ultra‐performance liquid chromatography tandem mass spectrometry. Treatment effects were evaluated by one‐way ANCOVA.ResultsIn the high PM dose group, we found a reduction of plasma methylglyoxal (MGO) and protein‐bound Nδ‐(5‐hydro‐5‐methyl‐4‐imidazolon‐2‐yl)‐ornithine (MG‐H1), as compared to placebo. We found a reduction of the endothelial dysfunction marker soluble vascular cell adhesion molecule‐1 (sVCAM‐1) in the low and high PM dose group and of soluble intercellular adhesion molecule‐1 (sICAM‐1) in the high PM dose, as compared to placebo. We found no treatment effects on insulin sensitivity, vascular function or other functional outcome measurements.ConclusionsThis study shows that PM is metabolically active and reduces MGO, AGEs, sVCAM‐1 and sICAM‐1, but does not affect insulin sensitivity and vascular function in abdominally obese individuals. The reduction in adhesion markers is promising because these are important in the pathogenesis of endothelial damage and atherosclerosis.
Funder
Center for Translational Molecular Medicine
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献